Compare Agnico Eagle Mines Ltd (AEM) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Crispr Therapeutics AG — how do they compare? Agnico Eagle Mines Ltd trades at $145.36 (market cap $75.10B), while Crispr Therapeutics AG trades at $59.25 (market cap $5.98B). The key difference: Agnico Eagle Mines Ltd is far larger — about 12.6× Crispr Therapeutics AG's market cap, and Agnico Eagle Mines Ltd pays a 1.2% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| AEM | CRSP | |
|---|---|---|
Market Cap | $75.10B | $5.98B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $76.78 |
52-Week Low | $116.14 | $44.34 |
Enterprise Value | $72.30B | $4.33B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CRISPR Therapeutics (CRSP) trades at $60.77, up 1.15% with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company maintains strong cash reserves despite negative profitability metrics, with recent FDA approval for Casgevy pediatric use expanding its commercial potential. Technical indicators show the stock trading near pivot point resistance at $61 with RSI levels suggesting potential overbought conditions.
While CRSP shows promising growth potential with its pioneering gene-editing technology and recent regulatory wins, investors face significant risks from persistent negative margins and cash burn. The stock offers 19.6% upside to the consensus price target of $72.67, but requires careful monitoring of commercialization progress and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
